Skip to main navigation Skip to search Skip to main content

Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.

Translated title of the contribution: Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
  • C.J. van der Woude
  • , P. Stokkers
  • , A.A. van Bodegraven
  • , G. van Assche
  • , Z. Hebzda
  • , L. Paradowski
  • , G. D'Haens
  • , S. Ghosh
  • , B. Feagan
  • , P. Rutgeerts
  • , G. Dijkstra
  • , D.J. de Jong
  • , B. Oldenburg
  • , M. Farhan
  • , T. Richard
  • , Y. Dean
  • , D.W. Hommes

Research output: Contribution to journalArticleAcademicpeer-review

Translated title of the contributionPhase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease.
Original languageUndefined/Unknown
Pages (from-to)1708-1716
Number of pages9
JournalInflammatory bowel diseases
Volume16
Issue number10
Publication statusPublished - 2010

Cite this